Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis

Company Overview

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company offering a range of branded, generic and injectable products across the United States, Europe, the Middle East and North Africa. Founded in Amman, Jordan in 1978 by Samih Darwazah, Hikma has grown from a single manufacturing plant into a diversified healthcare group. Today, the company is incorporated in the United Kingdom and trades in the U.S. over-the-counter market under the symbol HKMPY.

The company’s operations are organized into three main business segments. Its Branded division develops and markets proprietary prescription medicines in key markets across the Middle East and North Africa, focusing on cardiovascular, central nervous system and anti-infective therapies. The Generics arm supplies a broad portfolio of off-patent oral solids to hospitals, wholesalers and pharmacies, while its Injectables division produces sterile injectable medicines, including critical hospital-use products such as anaesthetics, anti-infectives and oncology treatments.

Hikma maintains a global network of manufacturing facilities in countries including Jordan, Portugal, Italy and the United States, where it operates Bedford Laboratories and West-Ward Pharmaceutical Corp. These sites are supported by development and quality-control centers that ensure compliance with international regulatory standards. The company’s geographic footprint extends to more than 50 countries, with a strong presence in emerging markets alongside established operations in North America and Europe.

Headquartered in London, Hikma Pharmaceuticals is led by Group Chief Executive Sigurdur “Siggi” Olafsson, who oversees strategy and operations across all business lines. The company’s board benefits from the experience of industry veterans and regional experts, enabling continued investment in research and manufacturing capabilities. Through strategic acquisitions and partnerships, Hikma aims to expand its therapeutic offerings and strengthen its position as a reliable supplier of high-quality pharmaceutical products worldwide.

Key Stats

• Today's Range: $53.71 to $53.71
• 50-Day Range: $51.96 to $56.94
• 52-Week Range: $45.97 to $59.26
• Volume: 366 shs
• Average Volume: 772 shs
• Market Capitalization: N/A
• P/E Ratio: 17.35
• Dividend Yield: 0.60%
• Price Target: N/A
• Consensus Rating: N/A

HKMPY Stock Analysis - Frequently Asked Questions

How have HKMPY shares performed this year?

Hikma Pharmaceuticals' stock was trading at $50.0075 at the start of the year. Since then, HKMPY stock has increased by 7.4% and is now trading at $53.71.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Record date for 5/12 Dividend: 3/21/2025
• Ex-Dividend for 5/12 Dividend: 3/21/2025
• Dividend Payable: 5/12/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/07/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HKMPY
• CIK: N/A
• Web: www.hikma.com
• Phone: 442073992760
• Fax: N/A
• Employees: 9,100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 17.35
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A